InvestorsHub Logo
Followers 1
Posts 35
Boards Moderated 0
Alias Born 02/06/2017

Re: Crusader post# 5658

Monday, 02/13/2017 5:17:20 PM

Monday, February 13, 2017 5:17:20 PM

Post# of 8169
So I looked at these two pubs and noticed two things:

1) they do not cover radiotherapeutics, but rather optical agents. Cellectar's optical agent has been in the pre-clinical stage in their pipeline for years now.
2) there is no 'validation'. The Nature Reviews article is, as the name indicates, a review about the current state of optical cancer detection during surgery. Has nothing to do with myeloma.

Just another paid-for article, and - as I predicted last week - no ORR numbers from the CEO today.

Don't you guys think it is weird that they have N=4 pts per cohort, but show you only N=2 in their graphs of today's deck?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CLRB News